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Background: Patient-specific and condition-specific measures are widely 
used in clinical practice and research to measure disability or change over time. 
While condition-specific outcome measures comprise a range of restrictions 
generally relevant for all patients, the Patient-Specific Functional Scale 
measures restrictions chosen by the individual patient. 
Objectives: Based on the hypothesis that patient-specific and condition-
specific scales deliver comparable results when used on group level. The aim of 
this study was to test for floor and ceiling effects, to evaluate construct validity 
and validity to change of the Patient-Specific Functional Scale when compared 
to condition-specific outcome measures. For this purpose, two datasets from 
patients with shoulder pain and low back pain were analyzed.
Methods: Patient-Specific Functional Scale scores were compared 
to the Shoulder Pain and Disability Index and the Roland Morris Disability 
Questionnaire at 4 time-points using stem-and-leaf-plots and correlations using 
Pearson’s r. Hypothesis-driven correlation levels for data interpretation were 
predefined, with r ≥0.75=high, r ≥0.5=moderate, r ≥0.25=low. 
Results: Patient-Specific Functional Scale floor effects were comparable 
to condition-specific outcome measures in both samples. At none of the time-
points did the Patient-Specific Functional Scale correlate with the condition-
specific outcome measures in the expected manner.
Conclusion: Hypotheses regarding expected ranges of correlation 
between the Patient-Specific Functional Scale and the condition-specific 
outcome measures for construct validity and validity to change were not met. 
While the use of the Patient-Specific Functional Scale in a clinical context has 
its advantages, the measure is not recommended for group-level evaluations. 
Keywords: Patient-centered outcome; Validity; Subacromial pain 
syndrome; Low back pain
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Background
For a therapist, it is essential to ascertain whether improvements 
in body function or structure also lead to increased activity and 
participation levels. Therefore, the use of assessment tools which 
can reflect the actual status or degree of restriction and which 
can measure patient’s change over time is of crucial importance. 
Improvements in body functions and structures are predominantly 
assessed through physical testing; activities and participation are 
commonly measured using questionnaires. Scores gathered using 
these measurement tools also allow comparison at a group level and 
enable patients, therapists and researchers to “measure” the impact of 
a disease, the progression over time or the effect of an intervention. 
However, since questionnaires often contain very specific items 
related to certain activities, it is possible that some items will not be 
relevant to all patients in the target group. By that, the importance 
of the individual items could vary between patients. Moreover, a 
“prefixed” item set may not include activities that are of importance 
to individual patients. Therefore, patients may be required to score 
questions that are only partly relevant to them. As a result, these 
standard questionnaires might not adequately reflect a patient’s 
individual restrictions or the change in these restrictions over time. 
In an attempt to solve this problem, the Patient-Specific Functional 
Scale (PSFS) was developed with the intention to monitor a patient’s 
progress based on relevant restrictions chosen by the individual 
himself [1]. The PSFS is comprised of 1 to 5 activities; each activity is 
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rated on an 11-point Numeric Rating Scale (NRS) from 0 (impossible 
to do) to 10 (no difficulties at all). The PSFS is easy to administer, 
and takes about five minutes to complete. However, the PSFS also has 
been used in the past by researchers to determine the current state 
of function and the development of activity restrictions over time 
on an average group level. By choosing this approach, researchers 
have moved away from the originally intended individual focus of 
the instrument and applied the PSFS to situations for which it was 
not developed or validated. From a test-theoretical perspective, there 
are numerous problems in deviating from the original construct. 
Firstly, the interpretation of an average score across self-selected 
activities by individuals is a challenge. For researchers and clinicians 
who are familiar with interpreting data on a clearly defined aspect 
of disability, it is tempting to interpret outcomes using the same 
approach; but in fact, one is averaging different constructs. Another 
problem is that floor or ceiling effects could occur if a patient chooses 
either lightly activities with scores at the lower end of the scale or 
severely restricted activities with scores at the upper end of the scale. 
In the first case, it is difficult to detect a positive development and 
in the second case to detect a negative development over time; this 
may affect results for validity to change analysis to a certain degree. 
Problems may also occur when the initially chosen activities become 
increasingly irrelevant as a problem as time gone by, due to either the 
patient’s improved condition or reduction in complaints or because of 
seasonal effects, when the activity becomes more and more irrelevant 
during follow up as for example snow shoveling in spring. Dependent 
on the activities chosen by the individual patient it could also be that 
outcomes in the PSFS indicate higher or lower disability levels for that 
patient compared to Condition-Specific Outcome Measures (CSOMs) 
and that scorings on the PSFS may differ significantly more between 
patients than their corresponding outcomes on a CSOM, where 
all patients rate the same standardized set of items. Despite these 
problems, which have not yet been adequately realized or addressed, 
several researchers have investigated the psychometric properties of 
the PSFS on a group level for a variety of musculoskeletal conditions. 
Results have been formulated as “promising”, since the PSFS has been 
reported as having good construct validity, discriminant validity, and 
responsiveness [2-4]. Based on these results we think that testing 
psychometric properties and comparisons at a group level can be 
justified by defining the PSFS as an instrument assessing “activity 
restriction based on items selected by an individual patient” as the 
overarching construct. We hypothesized that specific musculoskeletal 
disorders (in our example subacromial shoulder pain and low back 
pain) lead to specific activity restrictions and specific pain patterns. 
CSOMs in our case the Shoulder Pain and Disability Index (SPADI) 
and the Roland & Morris Disability Questionnaire (RMDQ), 
summarize these typical activities and include a range of tasks from 
easy to more difficult. These questionnaires were designed to include 
items that cover the whole range of items assumed relevant for a 
patient group, although not every item may be of equal importance 
to each individual patient. Therefore, we assume that many activity 
restrictions chosen by individual patients for their PSFS can be traced 
back or are closely related to items listed in the CSOMs. If this is the 
case, the PSFS could be approached as a construct and, because of 
the hypothesized close association between the operationalization 
of both types of measurement, assumed to deliver a relatively high 
correlation with the CSOM, especially in a cross-sectional analysis. 
However, there is also the possibility that the PSFS measures a different 
dimension not covered in the COSM. Taking these arguments into 
consideration, the aims of this paper are threefold: In two groups of 
patients, suffering from either Subacromial Pain Syndrome (SPS) or 
Low Back Pain (LBP), and using the CSOM as an external standard 
comparator: 1) To test for possible floor and ceiling effects of the 
PSFS; 2) To evaluate its construct validity compared to the CSOM, 
and 3) To assess the ability of the PSFS to detect changes over time 
with reference to an external anchor [5].
Methods
Data were used from two different datasets collected during 
randomized controlled trials investigating effects of physiotherapy 
interventions in a patient group with SPS and a second group 
with LBP in primary care. A detailed description of the inclusion 
processes, applied treatments and primary analyses can be found in 
the published study protocols [6,7] and trial results [8-11]. Ethical 
approval was granted by the ethics committee of the Ludwig-
Maximilians-University Munich, Germany (project-no. 018-10) 
for the SPS trial, and the Swiss Ethics Committee granted ethical 
approval (KEK-ZH-NR: 2010-0034/5) for the LBP trial. All patients 
in each trial gave informed consent. Datasets of the two samples were 
analyzed independently of each other.
Dataset 1 - SPS patients
Participants were recruited through referral for physiotherapy 
due to shoulder complaints. After baseline assessment, they were 
randomly assigned to either an intervention or a control group. The 
intervention group received exercise therapy plus manual therapy, 
while the control group received only exercise therapy. Baseline 
characteristics of the 90 participants included in the trial are presented 
in Table 1.
The primary outcome measure was the SPADI, a shoulder-
specific, self-reported questionnaire measuring pain and disability 
[12]. SPADI sub-scales for pain (items 1 to 5) and function (items 6 to 
13) are scored from 0 to 100, with higher scores reflecting higher pain 
or disability levels. Total SPADI score was calculated by averaging 
scores of the two sub-scales. The SPADI has been shown to be valid 
and highly sensitive [12,13]. The German version of the SPADI has 
also been shown to have excellent reliability and internal consistency 
[14]. The PSFS [1,15] was also applied. Patients were instructed to 
choose 3 activities important to them, in which they were impaired, 
and to rate their ability to perform those on an 11-point NRS from 
0 (impossible to do) to 10 (fully capable). The average score across 
all activities was calculated. For reasons of standardization, the PSFS 
has been rescaled in this paper, so that 0 now means “no difficulties 
at all” and 10 means “impossible to do”, in accordance with the other 
outcome measures used in this analysis. All measurement instruments 
were applied at Baseline (BL), after 5 weeks (T1), 12 weeks (T2), and 
at one year follow-up (T3).
Dataset 2 - LBP patients
A total of 106 patients with LBP, defined as pain persisting for 
longer than six weeks and with no radiating symptoms below the knee, 
were included in the original LBP trial. Eligible patients presented 
with LBP in combination with defined complaints associated with 
Movement Control Impairment (MCI). Other inclusion criteria were 
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a score of at least two positive out of six movement tests (representing 
MCI) and a minimal level of disability of 5 points on the RMDQ [7,16]. 
Participants were randomly allocated either to an intervention group 
that received an individual complaint-specific exercise program, or 
to a control group that received general exercise therapy. Baseline 
characteristics are presented in Table 1.
Primary outcome measure was the PSFS [1,15,17]. Patients 
received the same instructions as in the shoulder trial. A secondary 
outcome was the RMDQ, which measures LBP-related disability. 
It consists of 24 dichotomous questions to be answered with either 
“yes” or “no”, with a “yes” score meaning high disability. Reliability 
was shown to be high and construct and internal validity to be good, 
also for the German version [18-20]. All outcomes were measured 
at baseline (BL), at 9-12 weeks (T1), 6 months (T2), and at one year 
follow-up (T3).
An overview and description of all outcome measures for both 
datasets are provided in Table 2. For this study, we decided only to 
include those patients with complete data regarding variables relevant 
to our analysis.
Data analysis and hypotheses
Floor and ceiling effects: Since patients may be greatly restricted 
in their activities at the start of treatment, they may also have high 
scorings for their chosen activities on the PSFS. Because high or low 
scores at any time point could have influenced the measurement 
properties of the outcomes, data were checked for possible floor and 
ceiling effects by using stem-and-leaf-plots at every measurement 
point before validity to change was investigated. Floor and/or ceiling 
effects were assumed when more than 15% of values were within 10% 
of the highest and/or lowest possible scores.
Hypothesis 1: There are no floor or ceiling effects at any 
measurement point.
Construct validity: To test aspects of construct validity of the 
PSFS we calculated correlations between the PSFS and SPADI or 
RMDQ, respectively, at every measurement point using Pearson’s 
r. A high correlation was defined as r ≥0.75, a moderate correlation 
as r ≥0.5 and a low correlation as r ≥0.25. High correlations were 
expected for baseline scorings because both measurements should 
reflect the status of disability. For the consecutive time points, T1, 
T2, and T3 progressively decreasing correlations were expected: from 
high at baseline to low at T3, especially in patients showing good 
improvement. This also could be because patients were not allowed 
to change the initially chosen PSFS activities over the 1-year follow up 
period, an application of the PSFS often used in research and clinical 
practice nowadays. In consequence, we expected that these activities 
would become increasingly irrelevant for patients as their health 
status improved over time.
Hypothesis 2a: There is a high correlation between the PSFS and 
CSOMs (RMDQ/SPADI) at baseline.
Hypothesis 2b: The correlation between the PSFS and the 
CSOMs (RMDQ/SPADI) measured at every follow-up point in a 
cross-sectional independent way (T1, T2, and T3) is lower than the 
correlation of the preceding point: r-values will decrease from high at 
baseline to moderate, and to low at T3.
Validity to change: To test the ability of the PSFS to detect change 
over time we calculated correlations between the change scores in the 
SPADI/RMDQ and the change scores in the PSFS for the following 
intervals: BL to T1, T1 to T2, and T2 to T3. We expected that the 
correlation between change scores would be acceptable in the short 
term, but would diverge over the longer term. Therefore, our third 
hypothesis was:
Hypothesis 3: PSFS change scores show high correlations 
with both the SPADI and the RMDQ between BL to T1, moderate 
correlations between T1-T2, and low correlations between T2-T3. 
The CSOMs are used as external anchors.
Results
Participants
Complete datasets were available for 87 SPS-participants (96.7%), 
and for 60 LBP-participants (56.6%). Characteristics of both samples 
are described in Table 3.
Floor and ceiling effects (hypothesis 1)
For the PSFS no evidence of ceiling effects at any measurement 
point was found. Floor effects were found in the SPS sample at T2 
and T3, with 32% (n=28) and 52.9% (n=46), respectively, within 10% 
of the lowest possible score. However, at T2 these participants had a 
mean (SD) SPADI score of 3.7 (3.6) points with only three participants 
scoring 10 points or higher. At T3, the mean SPADI score was 2.5 
(3.6) with again only three participants scored 10 points or higher. In 
the LBP sample floor effects were found at T1, T2, and T3, increasing 
from 21.6% (n=13), 36.7% (n=22) to 43.3% (n=26), respectively. As 
seen in the SPS sample, the average scores of these patients on the 
RMDQ were also comparably low. Results are summarized in Table 4.
Construct validity (hypotheses 2a and 2b)
The PSFS correlated well with SPADI and RMDQ at baseline. 
However, correlation coefficients were below our predefined cut-
off level of r ≥0.75. Our hypothesis 2a, therefore, had to be rejected. 
Correlations for the time-points T1, T2 and T3 showed a progressive 
increase: we found the strongest correlations at T3, with r = 0.90 in the 
SPS and r = 0.74 in the LBP sample. This development was completely 
contrary to our hypothesis 2b. Based on these results, hypothesis 2b 
 SPS (n=90) LBP (n=106)
Age in years 51.8 (11.2) 41.6 (14.1)
Gender (female) %, n 51.1, 46 37.4, 40
Duration of the current episode in weeks 33.9 (42.8) --
Overall duration of complaints in years 8.7 (12.7) 10.0 (11.0)
SPADI/RMDQ total score 40.4 (17.0) 8.7 (3.3)
PSFS average score 6.0 (1.7) 5.7 (1.6)
GCPS total score -- 27.8 (10.4)
GCPS sub-score disability -- 12.4 (7.6)
FABQ total score 32.7 (17.4) 32.2 (14.7)
Table 1: Baseline demographic data and results for SPS and LBP patients initially 
included in the original trials (mean (SD) if not otherwise stated).
SD: Standard Deviation; SPADI: Shoulder Pain and Disability Index; RMDQ: 
Roland Morris Disability Questionnaire; PSFS: Patient-Specific Functional Scale; 
FABQ: Fear Avoidance Beliefs Questionnaire; GCPS: Graded Chronic Pain 
Scale (Total Score: 70; Pain Intensity: 0-30, Disability: 0-40); SPS: Subacromial 
Pain Syndrome; LBP: Low Back Pain.
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also had to be rejected. Detailed results are displayed in Table 5.
Validity to change (hypothesis 3)
Here we expected decreasing correlation coefficients for change 
scores over time. However, results did not support this hypothesis. 
Instead of decreasing correlation coefficients, we found alternating 
patterns that varied between samples. The SPS r-values varied in an 
down-up sequence, with the strongest correlation for the change 
score between T2 and T3. In contrast, the LBP sample showed an up-
down pattern. Here, a very low correlation was found between T2 and 
T3. Results are displayed in Table 5.
Discussion
The aim of this paper was to test the following hypotheses 
regarding the PSFS when compared to well-established CSOMs: no 
floor and ceiling effects, acceptable construct validity and validity 
to change over time. Two samples from different populations were 
analyzed and similar results were found. Four measurement points 
were incorporated in the analysis whereby it was possible to present 
the development of the relationship between the PSFS and the 
CSOMs over the period of one year. Other than for floor and ceiling 
effects results showed opposite effects than we hypothesized, resulting 
in the rejection of our hypotheses regarding construct validity and 
validity to change. These results demonstrate that the overarching 
construct defined in the introduction must be doubted. The PSFS 
certainly does not reflect change on a group level in the same way 
that CSOMs do. The development over time of the correlations 
Outcomes measures Dimension Scale Scorings
a) SPS    
Shoulder Pain and Disability Index 
(SPADI)






Items 1-5 scored on a 100mm VAS
Items 6-13 scored on a 100mm VAS
Mean of item scores. Higher scores mean higher pain/disability.
Patient-Specific Functional Scale 
(PSFS) SPS - related disability
0-10, 
continuous
11 point visual numeric rating scale (end descriptors of 0 = impossible to do, 10 = 
no difficulties at all)
b) LBP    
Patient-Specific Functional Scale 
(PSFS)




11 point visual numeric rating scale (end descriptors of 0 = impossible to do, 10 = 
no difficulties at all)
Roland-Morris Disability 
Questionnaire (RMDQ) LBP - related disability
0-24, 
continuous
Dichotomous questions (yes = with disability, no=no disability); Scores 0 – 24 
(minimal enrolment to trial RMDQ = 5)
Table 2: Outcome measures used in the two trials.
SPS: Subacromial Pain Syndrome; LBP: Low Back Pain; VAS: Visual Analogue Scale.
 SPS (n=87) LBP (n=60)
Age in years 52.0 (11.4) 41.8 (13.9)
Gender (female) %, n 49.4, 43 38.3, 23
Duration of the current SPS episode in weeks 33.6 (43.5) --
Overall duration of complaints in years 8.6 (12.9) 9.1 (10.4)
SPADI/RMDQ total score 41.0 (17.0) 8.7 (3.3)
PSFS average score 6.0 (1.6) 5.7 (1.6)
GCPS total score -- 26.5 (10.1)
GCPS sub-score disability -- 11.1 (7.4)
FABQ total score 32.0 (17.2) 29.3 (13.8)
Table 3: Baseline demographic data and results for SPS and LBP samples 
included in this analysis (mean (SD) if not otherwise stated).
BL T1 T2 T3
SPS sample (n= 87)
PSFS ≤1 N=0 (0%) N=13 (14.9%) N=28 (32.0%) N=46 (52.9%)
SPADI mean (SD) score* -- --  3.7 (3.6)  2.5 (3.6)
PSFS >9 N=5 (5.8%) N=0 (0%) N=2 (2.3%) N=2 (2.3%)
LBP sample (n = 60)
PSFS ≤1 N=0 (0%) N=13 (21.6%) N=22 (36.7%) N=26 (43.3%)
RMDQ mean (SD) score* -- 1.3 (1.6) 1.8 (3.0)  1.5 (1.8) 
PSFS > 9 N=1 (1.8%) N=0 (0%) N=0 (0%) N=0 (0%)
Table 4: Floor and ceiling effects. n= (%) of patients scoring within the highest and lowest 10% of the PSFS.
*If more than 15% scored in the lower or higher 10% range of the scale, the mean and (SD) of the SPADI/RMDQ score of this sub-sample is displayed. SD: Standard 
Deviation; SPADI: Shoulder Pain and Disability Index; RMDQ: Roland Morris Disability Questionnaire; PSFS: Patient-Specific Functional Scale; SPS: Subacromial 
Pain Syndrome; LBP: Low Back Pain.
 Outcome 
measure















12 monthsb SPS & 
LBP
SPADI 0.406 0.663 0.794 0.903 0.572 0.417 0.661
RMDQ 0.301 0.523 0.651 0.743 0.497 0.542 0.176
Table 5: Correlations (Pearson`s r) between PSFS and condition-specific disability scores.
BL: Baseline; r: Pearson’s Correlation Coefficient; a: Post Intervention; b: Final Follow Up; SPADI: Shoulder Pain and Disability Index; RMDQ: Roland Morris Disability 
Questionnaire; PSFS: Patient-Specific Functional Scale; SPS: Subacromial Pain Syndrome; LBP: Low Back Pain.
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between PSFS and CSOMs has led us to conclude that the underlying 
constructs are different and, therefore, should not be used for the 
same purpose. Although the PSFS has been used in several studies as 
a secondary outcome measure to analyze longitudinal development 
of activity restrictions on a group level [8,11,21-23] and seemed to 
perform well for this purpose, our data suggest that the underlying 
construct remains unclear. Therefore, we cannot recommend the use 
of the PSFS without taking into account that the underlying construct 
is besides different from CSOM also unclear to interpret on a group 
level, at the moment [24].
Other authors also have investigated validity aspects of the PSFS. 
Hall et al. [25] investigated responsiveness of RMDQ and PSFS in 
patients with LBP and attested both outcome measures an “acceptable” 
responsiveness. In a first step, they calculated correlations between 
RMDQ/PSFS and the Global Perceived Effect scale (GPE), which they 
used as an external reference standard for change. In a second step, 
they used a receiver operating characteristics (ROC) curve to assess 
responsiveness. This methodological approach provides information 
about the relationship between RMDQ/PSFS and GPE as an external 
indicator of change. Although GPE is often used for this purpose, 
GPE (change) scores might be more a reflection of the current health 
status than of true change and GPE might, therefore, be insufficient to 
serve as a valid external reference for change [26]. Furthermore, when 
using ROC it is necessary to dichotomize the external change scores, 
which leads to a loss of information on the magnitude of change [27]. 
Our purpose was to analyze whether the PSFS was responsive relative 
to our CSOMs. The different approach to Hall et al. [25] may explain 
the difference in conclusions drawn from these results.
Thoomes-de Graaf et al. [28] tested convergent validity between 
the PSFS and the Neck Disability Index (NDI) in patients with neck 
pain; they assumed that both tools measure the same construct of 
“activity limitations” and expected to find a strong baseline correlation 
between them. However, results showed only a moderate correlation.
Abbott and Schmitt [2] investigated concurrent validity (which 
would be defined as construct validity in the absence of a gold 
standard according to Mokkink et al. [5]) and validity to change of 
the PSFS in a sample with mixed acute and chronic musculoskeletal 
disorders. According to our classification system for the correlation 
coefficient, they found a moderate correlation between PSFS and 
CSOMs at baseline in the subgroup with upper extremity disorders 
and a low correlation in the subgroup with LBP. Interestingly these 
correlations were stronger at 6-month follow-up, which were similar 
to the outcomes in our samples. The moderate correlations found for 
change scores between baseline and follow-up at 6 months were also 
similar to ours (between baseline and our last measurement point 
at 1 year), although the use of different time frames may complicate 
this comparison. Similar results regarding construct validity were 
also found by Heldmann et al. [29] in LBP-patients. They used the 
Oswestry Disability Index (ODI) as reference measure and found 
low correlations at baseline and moderate correlations at follow-up. 
The fact that we obtained similar results to those of Abbott et al. [2] 
and Heldmann et al. [29] for patients with LBP and SPS has led us to 
the assumption that results could be independent of the condition 
specific population of interest. This assumption is underpinned by 
similar results found for lower extremity and neck disorders in the 
study by Abbott et al. [30], and by results from Stratford et al. [31] 
who also found low correlations between change scores of PSFS 
and CSOM used in patients who underwent total knee arthroplasty. 
In our opinion, it is more likely that the similarity of results of the 
mentioned studies and our study is mainly based on a basic difference 
between the constructs of the PSFS and CSOMs.
In another study, Mannberg-Bäckman et al. [32] investigated the 
validity and sensitivity to change of the PSFS in a group of patients 
after proximal humerus fracture. Although 62% of the chosen items 
in the PSFS were also represented in the CSOM, correlation between 
the two instruments was low, whereas sensitivity to change was high 
in both instruments. Resnik et al. [33] investigated responsiveness of 
several CSOMs and the PSFS in patients undergoing rehabilitation 
for upper limb prosthesis. The PSFS showed the largest effect sizes 
from all outcomes analyzed. This difference between PSFS and other 
outcomes was most obvious for long-term results, where PSFS still 
showed significant changes while most of the other instruments did 
not. The authors concluded that the PSFS was one of the outcome 
measures most responsive to change. Heldmann et al. [29] also 
concluded that the PSFS is more responsive than the Oswestry 
Disability Index (ODI) because they found higher effect sizes for 
the PSFS. However, effect sizes might be rather a reflection of 
quantitative properties in the study population (it is merely a measure 
focusing on individual changes) than necessarily of the validity of the 
instrument itself. Therefore, these results may alternatively suggest 
that the PSFS measures a different construct than CSOMs and that 
larger effect can be reached when using the PSFS instead of a CSOM, 
but do not clarify the construct underlying the PSFS. Originally, the 
PSFS was developed to address individual activity restrictions, to 
prioritize treatment goals, and, last but not least, to keep patients 
motivated by working on personally important goals. We would 
agree with using the PSFS for these purposes. We also would agree 
with using the PSFS for risk assessment [34] and to monitor short-
term effects in individual patients. The PSFS also may help to redirect 
focus towards value driven treatment goals chosen by the individual 
patients themselves and consequently on function and ability rather 
than pain and disability. Based on our data, we believe that the 
PSFS does not provide a clinically meaningful unidimensional scale 
comparable on a group level to a CSOM, because it aggregates not 
only heterogeneous functional items in one scale but also averages 
item-dependent scores. This makes it difficult to compare outcomes 
of the two types of measures on a group level in patients.
Limitations
Both of our samples contained mainly patients with chronic 
complaints and our results could be different from studies that 
investigate samples including acute patients. Furthermore, 
correlations based on the Pearson’s r measure the closeness to a 
linear relationship but the relationship between two measures may 
be close but non-linear which we did not analyze. Our values set for 
the Pearson’s correlation coefficient for the acceptance of the stated 
hypotheses were high and subjective to a certain degree; this led to 
a more conservative interpretation of the results. Our results for 
construct validity were mainly based on convergent validity; based on 
existing data it was not possible for us to analyze divergent validity.
Conclusions
Our hypotheses of the expected ranges of correlation between 
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the PSFS and the CSOM for construct validity and validity to change 
had to be rejected. While the use of the PSFS in a clinical context 
has its advantages, the measure is not recommended to assess the 
development of pathology or syndromes or to compare between 
patients on a group level.
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